Sara Lustigman

List of Publications by Year
in descending order

85	3,850	136950	133252
papers	citations	32 h-index	59 g-index

90	90	90	3461
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Draft Genome of the Filarial Nematode Parasite Brugia malayi. Science, 2007, 317, 1756-1760.	12.6	571
2	A Research Agenda for Helminth Diseases of Humans: The Problem of Helminthiases. PLoS Neglected Tropical Diseases, 2012, 6, e1582.	3.0	250
3	A Research Agenda for Helminth Diseases of Humans: Intervention for Control and Elimination. PLoS Neglected Tropical Diseases, 2012, 6, e1549.	3.0	163
4	RNA interference targeting cathepsin L and Z-like cysteine proteases of Onchocerca volvulus confirmed their essential function during L3 molting. Molecular and Biochemical Parasitology, 2004, 138, 165-170.	1.1	145
5	A Research Agenda for Helminth Diseases of Humans: Diagnostics for Control and Elimination Programmes. PLoS Neglected Tropical Diseases, 2012, 6, e1601.	3.0	138
6	The genome of Onchocerca volvulus, agent of river blindness. Nature Microbiology, 2017, 2, 16216.	13.3	107
7	Cathepsin L Is Essential for Embryogenesis and Development ofCaenorhabditis elegans. Journal of Biological Chemistry, 2002, 277, 3477-3486.	3.4	104
8	A gene family of cathepsin L-like proteases of filarial nematodes are associated with larval molting and cuticle and eggshell remodeling. Molecular and Biochemical Parasitology, 2004, 136, 227-242.	1.1	94
9	Cloning of a Cysteine Protease Required for the Molting of Onchocerca volvulus Third Stage Larvae. Journal of Biological Chemistry, 1996, 271, 30181-30189.	3.4	92
10	Repositioning of an existing drug for the neglected tropical disease Onchocerciasis. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 3424-3429.	7.1	91
11	Repurposing Auranofin as a Lead Candidate for Treatment of Lymphatic Filariasis and Onchocerciasis. PLoS Neglected Tropical Diseases, 2015, 9, e0003534.	3.0	88
12	Helminth Genomics: The Implications for Human Health. PLoS Neglected Tropical Diseases, 2009, 3, e538.	3.0	86
13	Characterization of an Onchocerca volvulus cDNA clone encoding a genus specific antigen present in infective larvae and adult worms. Molecular and Biochemical Parasitology, 1991, 45, 65-75.	1.1	79
14	Towards a recombinant antigen vaccine against Onchocerca volvulus. Trends in Parasitology, 2002, 18, 135-141.	3.3	78
15	A Research Agenda for Helminth Diseases of Humans: Towards Control and Elimination. PLoS Neglected Tropical Diseases, 2012, 6, e1547.	3.0	76
16	Characterization of a Novel Filarial Serine Protease Inhibitor, Ov-SPI-1, from Onchocerca volvulus, with Potential Multifunctional Roles during Development of the Parasite. Journal of Biological Chemistry, 2005, 280, 40845-40856.	3.4	66
17	Development of a Recombinant Antigen Vaccine against Infection with the Filarial Worm Onchocerca volvulus. Infection and Immunity, 2001, 69, 262-270.	2.2	62
18	Ivermectin Resistance in Onchocerca volvulus: Toward a Genetic Basis. PLoS Neglected Tropical Diseases, 2007, 1, e76.	3.0	62

#	Article	IF	Citations
19	Functional Analysis of the Cathepsin-Like Cysteine Protease Genes in Adult Brugia malayi Using RNA Interference. PLoS Neglected Tropical Diseases, 2009, 3, e377.	3.0	58
20	Immunity to Onchocerciasis: Cells from Putatively Immune Individuals Produce Enhanced Levels of Interleukin-5, Gamma Interferon, and Granulocyte-Macrophage Colony-Stimulating Factor in Response to Onchocerca volvulus Larval and Male Worm Antigens. Infection and Immunity, 2000, 68, 1905-1911.	2.2	56
21	Characterization of an Onchocerca volvulus L3-specific larval antigen, Ov-ALT-11Note: Nucleotide sequence data reported in this paper is available in the GenBankâ„¢ database under the accession numbers U96176 and AF044952.1. Molecular and Biochemical Parasitology, 1998, 96, 177-183.	1.1	49
22	In a bovine model of onchocerciasis, protective immunity exists naturally, is absent in drug-cured hosts, and is induced by vaccination. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 5971-5976.	7.1	47
23	Prediction pipeline for discovery of regulatory motifs associated with Brugia malayiÂmolting. PLoS Neglected Tropical Diseases, 2020, 14, e0008275.	3.0	46
24	Stage-Specific Transcriptome and Proteome Analyses of the Filarial Parasite Onchocerca volvulus and Its Wolbachia Endosymbiont. MBio, 2016, 7, .	4.1	45
25	Differential Cytokine and Antibody Responses to Adult and Larval Stages of Onchocerca volvulus Consistent with the Development of Concomitant Immunity. Infection and Immunity, 2002, 70, 2796-2804.	2.2	44
26	Onchocerca volvulus: Biochemical and morphological characteristics of the surface of third- and fourth-stage larvae. Experimental Parasitology, 1990, 71, 489-495.	1.2	43
27	Defining Brugia malayi and Wolbachia symbiosis by stage-specific dual RNA-seq. PLoS Neglected Tropical Diseases, 2017, 11, e0005357.	3.0	43
28	Identification and characterization of an Onchocerca volvulus cDNA clone encoding a microfilarial surface-associated antigen. Molecular and Biochemical Parasitology, 1992, 50, 79-93.	1.1	40
29	Brugia malayi Gene Expression in Response to the Targeting of the Wolbachia Endosymbiont by Tetracycline Treatment. PLoS Neglected Tropical Diseases, 2009, 3, e525.	3.0	40
30	Immune responses to third stage larvae of Onchocerca volvulus in interferonâ€gamma and interleukinâ€4 knockout mice. Parasite Immunology, 1998, 20, 319-324.	1.5	38
31	A Potential Role for the Interaction of Wolbachia Surface Proteins with the Brugia malayi Glycolytic Enzymes and Cytoskeleton in Maintenance of Endosymbiosis. PLoS Neglected Tropical Diseases, 2013, 7, e2151.	3.0	38
32	Sex chromosome evolution in parasitic nematodes of humans. Nature Communications, 2020, 11, 1964.	12.8	38
33	Vaccines to combat river blindness: expression, selection and formulation of vaccines against infection with Onchocerca volvulus in a mouse model. International Journal for Parasitology, 2014, 44, 637-646.	3.1	36
34	Onchocerca volvulus: The Road from Basic Biology to a Vaccine. Trends in Parasitology, 2018, 34, 64-79.	3.3	36
35	Recombinant Ov-ASP-1, a Th1-Biased Protein Adjuvant Derived from the Helminth Onchocerca volvulus, Can Directly Bind and Activate Antigen-Presenting Cells. Journal of Immunology, 2009, 182, 4005-4016.	0.8	35
36	The Onchocerciasis Vaccine for Africaâ€"TOVAâ€"Initiative. PLoS Neglected Tropical Diseases, 2015, 9, e0003422.	3.0	35

#	Article	IF	Citations
37	Oxfendazole mediates macrofilaricidal efficacy against the filarial nematode Litomosoides sigmodontis in vivo and inhibits Onchocerca spec. motility in vitro. PLoS Neglected Tropical Diseases, 2020, 14, e0008427.	3.0	31
38	Glucose and Glycogen Metabolism in Brugia malayi Is Associated with Wolbachia Symbiont Fitness. PLoS ONE, 2016, 11, e0153812.	2.5	31
39	Emodepside has sex-dependent immobilizing effects on adult Brugia malayi due to a differentially spliced binding pocket in the RCK1 region of the SLO-1 K channel. PLoS Pathogens, 2019, 15, e1008041.	4.7	30
40	CD4+-dependent immunity to Onchocerca volvulus third-stage larvae in humans and the mouse vaccination model: common ground and distinctions. International Journal for Parasitology, 2003, 33, 1161-1171.	3.1	29
41	Modelling Neglected Tropical Diseases diagnostics: the sensitivity of skin snips for Onchocerca volvulus in near elimination and surveillance settings. Parasites and Vectors, 2016, 9, 343.	2.5	28
42	Human Onchocerciasis: Modelling the Potential Long-term Consequences of a Vaccination Programme. PLoS Neglected Tropical Diseases, 2015, 9, e0003938.	3.0	28
43	A Research Agenda for Helminth Diseases of Humans: Basic Research and Enabling Technologies to Support Control and Elimination of Helminthiases. PLoS Neglected Tropical Diseases, 2012, 6, e1445.	3.0	27
44	Cysteine proteases during larval migration and development of helminths in their final host. PLoS Neglected Tropical Diseases, 2018, 12, e0005919.	3.0	27
45	Vaccination of Gerbils with Bm-103 and Bm-RAL-2 Concurrently or as a Fusion Protein Confers Consistent and Improved Protection against Brugia malayi Infection. PLoS Neglected Tropical Diseases, 2016, 10, e0004586.	3.0	25
46	Development of a toolkit for piggyBac-mediated integrative transfection of the human filarial parasite Brugia malayi. PLoS Neglected Tropical Diseases, 2018, 12, e0006509.	3.0	25
47	Development of a preliminary in vitro drug screening assay based on a newly established culturing system for pre-adult fifth-stage Onchocerca volvulus worms. PLoS Neglected Tropical Diseases, 2019, 13, e0007108.	3.0	24
48	Integrating Multiple Biomarkers to Increase Sensitivity for the Detection of Onchocerca volvulus Infection. Journal of Infectious Diseases, 2020, 221, 1805-1815.	4.0	23
49	Vaccination with a genetically modified Brugia malayi cysteine protease inhibitor-2 reduces adult parasite numbers and affects the fertility of female worms following a subcutaneous challenge of Mongolian gerbils (Meriones unguiculatus) with B. malayi infective larvae. International Journal for Parasitology, 2014, 44, 675-679.	3.1	21
50	Development of Onchocerca volvulus in humanized NSG mice and detection of parasite biomarkers in urine and serum. PLoS Neglected Tropical Diseases, 2018, 12, e0006977.	3.0	21
51	The case for vaccine development in the strategy to eradicate river blindness (onchocerciasis) from Africa. Expert Review of Vaccines, 2015, 14, 1163-1165.	4.4	20
52	Pyruvate produced by Brugia spp. via glycolysis is essential for maintaining the mutualistic association between the parasite and its endosymbiont, Wolbachia. PLoS Pathogens, 2019, 15, e1008085.	4.7	20
53	The Immunomodulatory Role of Adjuvants in Vaccines Formulated with the Recombinant Antigens Ov-103 and Ov-RAL-2 against Onchocerca volvulus in Mice. PLoS Neglected Tropical Diseases, 2016, 10, e0004797.	3.0	20
54	The Onchocerca volvulus Cysteine Proteinase Inhibitor, Ov-CPI-2, Is a Target of Protective Antibody Response That Increases with Age. PLoS Neglected Tropical Diseases, 2010, 4, e800.	3.0	19

#	Article	IF	Citations
55	Antibody responses against the vaccine antigens Ov-103 and Ov-RAL-2 are associated with protective immunity to Onchocerca volvulus infection in both mice and humans. PLoS Neglected Tropical Diseases, 2019, 13, e0007730.	3.0	18
56	Potential involvement of Brugia malayi cysteine proteases in the maintenance of the endosymbiotic relationship with Wolbachia. International Journal for Parasitology: Drugs and Drug Resistance, 2014, 4, 267-277.	3.4	17
57	Vaccination with recombinant Brugia malayi cystatin proteins alters worm migration, homing and final niche selection following a subcutaneous challenge of Mongolian gerbils (Meriones) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50	2.5	16
58	Ligand binding properties of two Brugia malayi fatty acid and retinol (FAR) binding proteins and their vaccine efficacies against challenge infection in gerbils. PLoS Neglected Tropical Diseases, 2018, 12, e0006772.	3.0	16
59	An Integrated Approach to Identify New Anti-Filarial Leads to Treat River Blindness, a Neglected Tropical Disease. Pathogens, 2021, 10, 71.	2.8	16
60	Characterisation of novel protein families secreted by muscle stage larvae of Trichinella spiralis. International Journal for Parasitology, 2009, 39, 515-524.	3.1	15
61	Lessons from the genomes and transcriptomes of filarial nematodes. Molecular and Biochemical Parasitology, 2017, 215, 23-29.	1.1	14
62	Macrofilaricidal Benzimidazoleâ€“Benzoxaborole Hybrids as an Approach to the Treatment of River Blindness: Part 2. Ketone Linked Analogs. ACS Infectious Diseases, 2020, 6, 180-185.	3.8	14
63	Efficacy of subcutaneous doses and a new oral amorphous solid dispersion formulation of flubendazole on male jirds (Meriones unguiculatus) infected with the filarial nematode Brugia pahangi. PLoS Neglected Tropical Diseases, 2019, 13, e0006787.	3.0	13
64	Nearly Complete Genome Sequence of Brugia malayi Strain FR3. Microbiology Resource Announcements, 2020, 9, .	0.6	13
65	Defining the target and the effect of imatinib on the filarial c-Abl homologue. PLoS Neglected Tropical Diseases, 2017, 11, e0005690.	3.0	12
66	Macrofilaricidal Benzimidazoleâ€“Benzoxaborole Hybrids as an Approach to the Treatment of River Blindness: Part 1. Amide Linked Analogs. ACS Infectious Diseases, 2020, 6, 173-179.	3.8	11
67	Onchocerca volvulus bivalent subunit vaccine induces protective immunity in genetically diverse collaborative cross recombinant inbred intercross mice. Npj Vaccines, 2021, 6, 17.	6.0	11
68	The role of 'omics' in the quest to eliminate human filariasis. PLoS Neglected Tropical Diseases, 2017, 11, e0005464.	3.0	11
69	Short-course quinazoline drug treatments are effective in the Litomosoides sigmodontis and Brugia pahangi jird models. International Journal for Parasitology: Drugs and Drug Resistance, 2020, 12, 18-27.	3.4	10
70	Drugs that target early stages of Onchocerca volvulus: A revisited means to facilitate the elimination goals for onchocerciasis. PLoS Neglected Tropical Diseases, 2021, 15, e0009064.	3.0	10
71	The Potency of an Anti-MERS Coronavirus Subunit Vaccine Depends on a Unique Combinatorial Adjuvant Formulation. Vaccines, 2020, 8, 251.	4.4	9
72	Development and validation of an Onchocerca ochengi adult male worm gerbil model for macrofilaricidal drug screening. PLoS Neglected Tropical Diseases, 2019, 13, e0007556.	3.0	8

#	Article	IF	Citations
73	The parasite-derived rOv-ASP-1 is an effective antigen-sparing CD4 + T cell-dependent adjuvant for the trivalent inactivated influenza vaccine, and functions in the absence of MyD88 pathway. Vaccine, 2018, 36, 3650-3665.	3.8	7
74	Development of a recombinant vaccine against human onchocerciasis. Expert Review of Vaccines, 2021, 20, 1459-1470.	4.4	6
75	Preliminary evaluations of 3-dimensional human skin models for their ability to facilitate in vitro the long-term development of the debilitating obligatory human parasite Onchocerca volvulus. PLoS Neglected Tropical Diseases, 2020, 14, e0008503.	3.0	6
76	Vaccination with novel low-molecular weight proteins secreted from Trichinella spiralis inhibits establishment of infection. PLoS Neglected Tropical Diseases, 2020, 14, e0008842.	3.0	5
77	Advancing a Human Onchocerciasis Vaccine From Antigen Discovery to Efficacy Studies Against Natural Infection of Cattle With Onchocerca ochengi. Frontiers in Cellular and Infection Microbiology, 2022, 12, 869039.	3.9	5
78	Co-Administration of Adjuvanted Recombinant Ov-103 and Ov-RAL-2 Vaccines Confer Protection against Natural Challenge in A Bovine Onchocerca ochengi Infection Model of Human Onchocerciasis. Vaccines, 2022, 10, 861.	4.4	5
79	Pyrvinium Pamoate and Structural Analogs Are Early Macrofilaricide Leads. Pharmaceuticals, 2022, 15, 189.	3.8	4
80	Aspartyl Protease Inhibitors as Anti-Filarial Drugs. Pathogens, 2022, 11, 707.	2.8	4
81	Response to the Letter to the Editor by Eberhard et al.. Parasites and Vectors, 2017, 10, 240.	2.5	0
82	Title is missing!. , 2020, 14, e0008503.		0
83	Title is missing!. , 2020, 14, e0008503.		0
84	Title is missing!. , 2020, 14, e0008503.		0
85	Title is missing!. , 2020, 14, e0008503.		0